Melatonin Effect on Platelet Count in Patients with Liver Disease
Gastroenterology and Hepatology from Bed to Bench,
,
23 August 2021
https://doi.org/10.22037/ghfbb.v14i4.2168
Abstract
Aim:
Thrombocytopenia occurs by exacerbating severity of liver disease. Reduction in the secretion of thrombopoetin, as an intrinsic hormone mainly produced by liver, plays an important role in this complication induced by liver disease. A positive effect of melatonin on platelet count in the patients with chronic liver disease was reported in the current study.
Method:
Design of this study was a double-blind, cross-over, placebo-controlled pilot study. The patients with liver disease were given two 5 mg pearls of melatonin or placebo for two weeks and after 2 weeks wash out period, we switched their groups. The liver function test and platelets count were assessed once at the beginning and once at the end of each phase of the study.
Result:
In the current study, 40 patients with eligible criteria were included. The average platelet count has significantly increased by melatonin in comparison with placebo (from 175.67±92.84 to 191.10±98.82 vs from 185.22±98.39 to 176.45±91.45) (p-value <0.001). Also, melatonin significantly reduced ALT, AST, total bilirubin, and direct and MELD scores in the patients with liver disease (p-value<0.05).
Conclusion
Melatonin may increase platelet count and inhibit thrombocytopenia in the patients with liver disease; however, more investigations are needed to confirm the obtained result.
- Platelet, Melatonin, Liver disease, Thrombopoietic properties
References
2. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23(8):1055-65. doi:10.1111/j.1365-2036.2006.02889.x.
3. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95(10):2936-9. doi:10.1111/j.1572-0241.2000.02325.x.
4. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7(6):689-95. doi:10.1016/j.cgh.2009.02.021.
5. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54(5):894-900. doi:10.1016/j.jhep.2010.08.018.
6. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50. doi:10.2147/hmer.s74612.
7. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol. 1999;94(7):1918-22. doi:10.1111/j.1572-0241.1999.01231.x.
8. Tuli HS, Kashyap D, Sharma AK, Sandhu SS. Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci. 2015;135:147-57. doi:10.1016/j.lfs.2015.06.004.
9. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr Neuropharmacol. 2017;15(3):434-43. doi:10.2174/1570159x14666161228122115.
10. Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5(2):126-9. doi:10.1007/bf01262569.
11. Lissoni P, Mandala M, Rossini F, Fumagalli L, Barni S. Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin. Hematology. 1999;4(4):335-43. doi:10.1080/10245332.1999.11746457.
12. Di Bella L, Rossi MT, Scalera G. Perspectives in pineal functions. Prog Brain Res. 1979;52:475-8. doi:10.1016/s0079-6123(08)62954-4.
13. Dellinger RP, Schorr CA, Levy MM. A users' guide to the 2016 Surviving Sepsis Guidelines. Intensive Care Med. 2017;43(3):299-303. doi:10.1007/s00134-017-4681-8.
14. Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1(8638):574-6. doi:10.1016/s0140-6736(89)91608-5.
15. Cohen J. Statistical power analysis for the behavioral sciences. Routledge; 2013.
16. Wang Y, Wang P, Zheng X, Du X. Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:7895-908. doi:10.2147/ott.s174100.
17. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. doi:10.1182/blood-2008-07-162503.
18. Kalambokis G, Tsianos EV. Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count. Am J Gastroenterol. 2010;105(12):2705-7. doi:10.1038/ajg.2010.364.
19. Chojnacki C, Błońska A, Chojnacki J. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment. 2017;2017:3204504. doi:10.1155/2017/3204504.
20. Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res. 2017;6:40. doi:10.4103/2277-9175.204593
- Abstract Viewed: 0 times
